FDA Advisory Committee recommends Triferic for Chronic Kidney Disease- Rockwell Medical
Rockwell Medical, Inc. (RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism has announced that the Oncologic Drugs Advisory Committee (ODAC) of the FDA recommended that the Phase III Triferic efficacy and safety results support a positive benefit/risk to treat iron loss to maintain hemoglobin in patients with hemodialysis-dependent stage 5 Chronic Kidney Disease (CKD). The ODAC voted in favour of Triferic by a vote of 8 to 3.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins